Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabor E Linthorst

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Medical Genetics|January 18, 2015
Plasma globotriaosylsphingosine in relation to phenotypes of Fabry diseaseBouwien E Smid, Linda van der Tol, Marieke Biegstraaten, et al.
Molecular Genetics and Metabolism|April 10, 2013
Fabry patients' experiences with the timing of diagnosis relevant for the discussion on newborn screeningMachtelt G Bouwman, Minke H de Ru, Gabor E Linthorst, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2010
[Recurrent rhabdomyolysis: screening for underlying disease]Rodi Zutt, Anneke J van der Kooi, Gabor E Linthorst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 5, 2003
alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry diseaseGabor E Linthorst, Carla E M Hollak, Johanna C Korevaar, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 17, 2009
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, David G Warnock, Maryam Banikazemi, et al.
The Journal of Clinical Endocrinology and Metabolism|September 26, 2018
The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International CollaborationIrene C Huffnagel, Fiza K Laheji, Razina Aziz-Bose, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Biochimica Et Biophysica Acta|September 21, 2010
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapyMariëlle J van Breemen, Saskia M Rombach, Nick Dekker, et al.
Plos One|July 12, 2007
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgAnouk C Vedder, Gabor E Linthorst, Gunnar Houge, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Medical Genetics|January 18, 2015
Plasma globotriaosylsphingosine in relation to phenotypes of Fabry diseaseBouwien E Smid, Linda van der Tol, Marieke Biegstraaten, et al.
Molecular Genetics and Metabolism|April 10, 2013
Fabry patients' experiences with the timing of diagnosis relevant for the discussion on newborn screeningMachtelt G Bouwman, Minke H de Ru, Gabor E Linthorst, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2010
[Recurrent rhabdomyolysis: screening for underlying disease]Rodi Zutt, Anneke J van der Kooi, Gabor E Linthorst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 5, 2003
alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry diseaseGabor E Linthorst, Carla E M Hollak, Johanna C Korevaar, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 17, 2009
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, David G Warnock, Maryam Banikazemi, et al.
The Journal of Clinical Endocrinology and Metabolism|September 26, 2018
The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International CollaborationIrene C Huffnagel, Fiza K Laheji, Razina Aziz-Bose, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Biochimica Et Biophysica Acta|September 21, 2010
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapyMariëlle J van Breemen, Saskia M Rombach, Nick Dekker, et al.
Plos One|July 12, 2007
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgAnouk C Vedder, Gabor E Linthorst, Gunnar Houge, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
Pageof 7